DAMORA THERAPEUTICS INC (DMRA)
NASDAQHealth CareBiotechnologySnapshot 2026-09-09
$26.27-9.94%
Close 2026-09-09 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-09
Warn: Management is running behind on a stated commitment.
Damora is stabilizing leadership with a new CEO and CFO successor. The company has $535 million in cash as of early 2026, supporting its operations. Operating losses are managed around $30 million per quarter while advancing drug development. Inclusion in Russell 2000 Growth and positive analyst views may improve visibility.
Damora remains loss-making with negative EPS expected through 2027. Leadership changes have been volatile, including CFO departure and accounting firm dismissal. Operating losses and cash burn continue, risking liquidity. The biotech pipeline faces typical clinical and regulatory risks.
The stock trades about 25% below our fair value near $40, reflecting cautious market views. The market expects continued losses and uncertain growth, while our view sees potential if leadership and cash management stabilize.
Breaks if: cash and equivalents fall below $500 million by 2026-Q4
Preserve strong cash position to support Phase 3 development of DMR-001 and ongoing operations.
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a speculative growth opportunity. The company is currently in a volatile state with mixed management priorities and elevated risk factors.
The market appears to have low expectations regarding DMRA's fragility, as no significant fragility gates have been triggered. However, the current valuation reflects the company's loss-making status and the uncertainty surrounding its future performance.
Fundamentals are likely to remain under pressure due to persistent operating losses and negative cash flow. Recent changes in management and a decline in company momentum add to the uncertainty in the near term.
The future of DMRA hinges on its ability to manage operating losses and maintain financial liquidity. Additionally, the company's performance may be influenced by sector trends and the outcomes of upcoming earnings reports from key industry players.
The most important moves since the prior daily snapshot.
Our read on the company is unchanged since the prior snapshot.
as of 2026-09-09
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Newly stated in 2026-Q1. Management reported approximately $535 million of cash and cash equivalents as of February 28, 2026, providing financial runway into Phase 3 development of DMR-001. No subsequent quarters restated this priority, so delivery trajectory is unconfirmed beyond initial statement.
“Strong financial position with approximately $535 million of cash and cash equivalents as of February 28, 2026, with anticipated runway into Phase 3 development of DMR-001”
Breaks if: CEO or CFO roles become vacant or unstable again within next 4 quarters
Manage executive changes including CEO appointment and CFO departure to ensure leadership continuity.
Stated in 2 of last 2 quarters. Management disclosed CEO appointment in 2026-Q1 and CFO departure in 2026-Q2. These leadership changes are recent and ongoing, reflecting active management of executive transitions.
“CFO Lori Firmani is departing with a successor appointed.”
“Jennifer Jarrett was appointed as President and Chief Executive Officer.”
Breaks if: operating loss worsens beyond -$30 million per quarter over next 4 quarters
Over the next 1 to 3 years, DMRA faces significant challenges that could impact its recovery trajectory. Not investment advice.